NetworkNewsBreaks

TuesdayFeb 14, 2023 1:07 pm

NetworkNewsBreaks – IBN to Shine the Spotlight on Health Equity in Clinical Trials Congress

IBN (“InvestorBrandNetwork”), an innovative corporate communications firm and content distributor, today announced its collaboration with Kisaco Research for its upcoming Health Equity in Clinical Trials Congress, which is slated to take place at the beautiful Hilton Boston Back Bay on Feb. 22-23, 2023. Kisaco is a leader in combining state-of-the-art conference production with high-impact networking to drive conversations between marquee organizations, policymakers, academic institutions, medtech and biopharma companies. The upcoming event aims to help facilitate change for underrepresented communities through industry action and technology across the animal health, beauty, health and wellness, AI and tech, drug development, women’s health, legal…

Continue Reading

TuesdayFeb 14, 2023 12:53 pm

NetworkNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Schedules Release of Q4 and FY 2022 Financial Results, Earnings Call

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, today announced that it will provide a business update and release its financial results for the fourth quarter and full year 2022 following the close of the market on Tuesday, March 14, 2023. Cepton will host a conference call and webcast at 2:30 p.m. PT (5:30 p.m. ET) that same day. Interested parties may join the call by dialing 1-877-300-8521 (toll-free) or 1-412-317-6026 (international) and visiting Cepton’s Investor Relations page to access the live webcast. A telephonic replay will be available approximately two hours after the live…

Continue Reading

TuesdayFeb 14, 2023 11:53 am

NetworkNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms US-Based Subsidiary with Focus to Expand Innovation Platforms

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the formation of a U.S.-based wholly owned subsidiary, Pearsanta Inc. The move intends to accelerate the expansion of Aditxt’s second program, AditxtScore(TM), through future strategic revenue and growth-oriented transactions. According to the update, Anthony Voorhies, currently the head of the AditxtScore(TM) division, will serve as president of Pearsanta. Voorhies has over 20 years of clinical diagnostics and healthtech industry experience and, under his leadership, the AditxtScore(TM) division has successfully grown from inception to commercialization and revenues in just…

Continue Reading

TuesdayFeb 14, 2023 11:42 am

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Launches New Program Targeting Unmet Medical Needs for Alcohol Misuse

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced the launch of a new research and development program focused on unmet medical needs for alcohol misuse. “Alcohol intoxication is a common presentation in many patients who visit hospital emergency rooms, and I see this during every one of my shifts,” said Dr. Albert Wong, a member of FSD Pharma’s expert advisory committee and a psychiatrist in the emergency department at the Centre…

Continue Reading

TuesdayFeb 14, 2023 11:32 am

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q3 Financial Report, Corporate Highlights

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is reporting on its third quarter performance as well as recent business highlights; the report is for the period ended Dec. 31, 2022. In the report, the company noted that it had received approval from an independent ethics committee in the Netherlands to begin the first-in-human dosing of its CYB004 through a protocol amendment to its ongoing phase 1 CYB004-E trial; CYB004 is the company’s proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule. The company is also making progress on its phase 1/2a clinical trial evaluating CYB003 for the potential treatment…

Continue Reading

TuesdayFeb 14, 2023 11:15 am

NetworkNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Announces Promising Data for Casiterita and Iska Iska Properties

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) today announced results of additional modeling of ground magnetic data and completion of an initial Induced Polarization/Resistivity survey (“IP/Res”) on the Casiterita property adjoining the Iska Iska Silver-Tin Polymetallic property to the southwest. The new data, combined with previous magnetic modeling and borehole IP/Res surveys (“BHIP”) on Iska Iska, have significantly enhanced the understanding of the overall geological environment on both properties and outlined major new targets for exploration on the optioned Casiterita. “Geophysics continues to be a very effective exploration tool at Iska Iska and now at the Casiterita property,” said…

Continue Reading

TuesdayFeb 14, 2023 10:48 am

NetworkNewsBreaks – CISO Global Inc. (NASDAQ: CISO) Shares Details on Proposed Public Offering

CISO Global Inc. (NASDAQ: CISO), formerly Cerberus Cyber Sentinel Corp., an industry leader in global cybersecurity and compliance services based in Scottsdale, Arizona, today commenced an underwritten public offering of its common stock, with Cantor Fitzgerald & Co. acting as the sole book-running manager. According to the release, the company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. CISO aims to utilize proceeds from the offering toward a variety of general corporate purposes, including working capital, capital expenditures, repayment and refinancing…

Continue Reading

TuesdayFeb 14, 2023 10:38 am

NetworkNewsBreaks – Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) Releases Pricing of Underwritten Public Offering to Total Estimated $15M

Sonnet BioTherapeutics (NASDAQ: SONN), a clinical-stage company developing innovative targeted biologic drugs, is reporting the pricing of its underwritten public offering; the offering consists of 13,888,888 shares of common stock or common stock equivalents, including prefunded warrants to purchase shares of common stock in lieu of shares of common stock and investor warrants to purchase up to an aggregate of 27,777,776 shares of common stock. According to the announcement, the common stock shares (or prefunded warrants in lieu thereof) are being combined and sold with one investor warrant enabling the purchase of two shares of common stock at a combined…

Continue Reading

MondayFeb 13, 2023 3:03 pm

NetworkNewsBreaks – EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) Poised to Cement Its Status as North American Leader in RNG

EverGen (TSX.V: EVGN) (OTCQX: EVGIF), a leading Canadian renewable energy company and Canada’s renewable natural gas (“RNG”) infrastructure platform, owns three projects in its home province of British Columbia and moved eastward in 2022, making large investments in projects in Alberta and Ontario. “Moving East, EverGen completed its acquisition of a 67% interest in Alberta’s Grow the Energy Circle Ltd., GrowTEC for short, which is currently in the first phase of a core RNG expansion project designed to produce ~80,000 GJ/year of RNG. The facility will then move into the second phase of the project, which is expected to produce…

Continue Reading

MondayFeb 13, 2023 2:52 pm

NetworkNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Launches Epitome of Everything That Matters in Lidar Manufacturing

Cepton (NASDAQ: CPTN) recently announced the launch of its latest innovative product: a new game-changing lidar called Vista(R)-X120 Plus. “Building on Cepton’s existing Vista-X90 lidar – an already established, groundbreaking automotive-grade lidar expected to be deployed in the company’s flagship ADAS lidar series production program – the Vista-X120 Plus aspires to raise another bar in the lidar market. With a reported 500% increase in data rate, 30° wider field of view, over 20% reduction in size, and 50% reduction in height, the Vista-X120 Plus appears to be the epitome of everything that matters in lidar manufacturing: safety, autonomy, software definability,…

Continue Reading